IRON - Company ID 0001816736
Disc Medicine, Inc. trades as IRON and has a market capitalization of $3.07 B, making it the #1804 largest US-listed company by market value. This page tracks Disc Medicine, Inc. through 704 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| Insider trade | 4 | 2026-04-15 |
| Insider trade | 4 | 2026-04-15 |
| Insider sale notice | 144 | 2026-04-13 |
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress | Disc Medicine Inc.
Disc Medicine to Participate in Upcoming Investor Conferences | Disc Medicine Inc.
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update | Disc Medicine Inc.
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting | Disc Medicine Inc.
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria | Disc Medicine Inc.
The largest companies sharing Disc Medicine, Inc.'s SEC industry classification (pharmaceutical preparations).
Disc Medicine, Inc. (IRON) has a market capitalization of $3.07 B as of 2026-07-09, ranking #1804 among US-listed companies.
In its latest fiscal year Disc Medicine, Inc. reported a net loss of $212.18M.